Amicus Therapeutics 過去の業績
過去 基準チェック /06
Amicus Therapeutics has been growing earnings at an average annual rate of 6.7%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 31.8% per year.
主要情報
6.7%
収益成長率
18.8%
EPS成長率
| Biotechs 業界の成長 | 12.9% |
| 収益成長率 | 31.8% |
| 株主資本利益率 | -192.3% |
| ネット・マージン | -71.9% |
| 前回の決算情報 | 31 Dec 2022 |
最近の業績更新
Recent updates
収支内訳
Amicus Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Dec 22 | 329 | -237 | 213 | 277 |
| 30 Sep 22 | 323 | -264 | 216 | 298 |
| 30 Jun 22 | 321 | -281 | 215 | 285 |
| 31 Mar 22 | 318 | -270 | 204 | 289 |
| 31 Dec 21 | 306 | -250 | 193 | 272 |
| 30 Sep 21 | 294 | -239 | 179 | 266 |
| 30 Jun 21 | 282 | -252 | 171 | 277 |
| 31 Mar 21 | 267 | -254 | 163 | 283 |
| 31 Dec 20 | 261 | -277 | 156 | 308 |
| 30 Sep 20 | 246 | -295 | 156 | 321 |
| 30 Jun 20 | 227 | -293 | 158 | 310 |
| 31 Mar 20 | 209 | -325 | 166 | 311 |
| 31 Dec 19 | 182 | -356 | 170 | 286 |
| 30 Sep 19 | 160 | -345 | 272 | 145 |
| 30 Jun 19 | 131 | -442 | 265 | 224 |
| 31 Mar 19 | 109 | -419 | 251 | 188 |
| 31 Dec 18 | 91 | -349 | 127 | 271 |
| 30 Sep 18 | 73 | -340 | 117 | 251 |
| 30 Jun 18 | 64 | -293 | 106 | 154 |
| 31 Mar 18 | 49 | -279 | 97 | 151 |
| 31 Dec 17 | 37 | -284 | 88 | 141 |
| 30 Sep 17 | 25 | -273 | 82 | 137 |
| 30 Jun 17 | 16 | -208 | 78 | 122 |
| 31 Mar 17 | 9 | -211 | 78 | 109 |
| 31 Dec 16 | 5 | -200 | 71 | 105 |
| 30 Sep 16 | 2 | -184 | 72 | 88 |
質の高い収益: FOLD * is currently unprofitable.
利益率の向上: FOLD * is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: FOLD * is unprofitable, but has reduced losses over the past 5 years at a rate of 6.7% per year.
成長の加速: Unable to compare FOLD *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: FOLD * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.8%).
株主資本利益率
高いROE: FOLD * has a negative Return on Equity (-192.26%), as it is currently unprofitable.